WuXi AppTec Delisted From 1260H List: What It Means for Sponsors

The Pentagon removed WuXi AppTec from its Section 1260H list after a court injunction. Here is what changes for sponsors, and what BIOSECURE still could do.

Last updated: November 12, 2026

Quick answer: The Defense Department delisted WuXi AppTec from its Chinese military companies list in a Federal Register notice published November 10, 2026, to comply with an August 7 preliminary injunction. The removal is expressly without prejudice to relisting, and the separate BIOSECURE Act track through OMB keeps running.

Scope: what the delisting does and does not change for drug sponsors, CDMO buyers and investors, based on the Federal Register notice, Defense Department guidance and attributed legal analysis.

What exactly happened to WuXi AppTec’s 1260H designation?

The Defense Department published a notice titled “Notice of Removal of Designated Chinese Military Company” stating that WuXi AppTec should be removed from the Section 1260H list published June 10, 2026. The notice says the decision complies with the August 7, 2026 order of the federal district court in Washington granting WuXi AppTec’s motion for a preliminary injunction.

The notice is dated November 5, was filed for public inspection November 9 and published November 10. The injunction it cites bars the department from “enforcing, implementing, or otherwise giving effect to” the designation. The decision was made by the Deputy Secretary (the notice uses both “Defense” and “War” for the department).

WuXi AppTec told the Hong Kong exchange that the decision “relieves the company from further adverse consequences of the 1260H designation,” according to Reuters. The company added that it remains committed to serving its customers.

Why did a court block the designation?

The court found the department’s justification did not hold up, according to a September analysis by Greenberg Traurig of the case, WuXi AppTec Co., Ltd. v. U.S. Dep’t of Defense, No. 1:26-cv-02069 (D.D.C.). The firm says the department’s reasoning rested on indirect state ownership and military affiliation claims that the court found deficient.

Greenberg Traurig reports that a cited 5.32% stake was in fact an AVIC fund’s portfolio allocation, with the actual holding in WuXi AppTec “closer to 0.001%.” The court also accepted irreparable harm because customers and suppliers cancelled contracts within weeks of the June listing, per the same analysis.

WuXi AppTec filed its complaint in the District of Columbia on June 11, three days after the department released the expanded list on June 8, according to Investing.com and Reuters. Reuters reported the list grew to 188 entities in that update.

Can the Pentagon put WuXi AppTec back on the list?

Yes. The notice says the delisting is “without prejudice to relisting the entity on additional or supplementary grounds.” A preliminary injunction is not a final ruling, and the merits and any appeal remain open.

That language matters for anyone writing a supplier risk memo. The department has signaled it can rebuild a designation on a different record, and Section 1260H requires the list to be republished annually through December 31, 2030, per the notice. Each annual update is a fresh relisting window.

What does the delisting change under Section 805?

It removes WuXi AppTec from the trigger for the Defense Department’s own contracting ban. Under Section 805 of the fiscal 2024 NDAA, the department cannot enter into, renew or extend contracts with 1260H listed entities starting June 30, 2026, according to the department’s Office of Industrial Base Policy.

The indirect ban starts June 30, 2027 and reaches contracts for goods or services that incorporate goods or services produced or developed by listed entities, per the same office. That second phase was the larger worry for drug and device companies that sell to the Defense Department, because it reaches suppliers of suppliers. With WuXi AppTec off the list, neither phase applies to it unless it is relisted.

Clock	Date	Does the delisting stop it for WuXi AppTec?
Section 805 direct contracting ban (DoD)	In force since June 30, 2026	Yes, while delisted
Section 805 indirect ban (DoD)	June 30, 2027	Yes, while delisted
Annual 1260H list republication	Each year through Dec 31, 2030	No, relisting is expressly allowed
OMB BIOSECURE list of biotechnology companies of concern	Due by Dec 18, 2026 (per law firm analyses)	No, OMB has a separate designation path
FAR revision that switches on BIOSECURE prohibitions	Outer limit about June 2028 (Greenberg Traurig estimate)	Depends on OMB’s list

Table: BioMed Nexus, built from the Defense Department Section 805 page, the November 10 Federal Register notice and attributed Greenberg Traurig, Ropes & Gray and Latham & Watkins analyses.

How does this interact with the BIOSECURE Act?

BIOSECURE became law as Section 851 of the fiscal 2026 NDAA, signed December 18, 2025, according to Ropes & Gray, Arnold & Porter and Latham & Watkins. It bars federal contracts, grants and loans tied to biotechnology equipment or services from “biotechnology companies of concern.”

Those law firms describe two routes onto that list. One covers 1260H listed entities that OMB determines are involved in biotechnology equipment or services. The other lets OMB designate a company directly if it is controlled by or acts for a foreign adversary government, works in biotechnology and poses a national security risk.

The delisting closes the first route for now. It does not touch the second. Greenberg Traurig says the injunction binds only the Defense Department, not OMB, and that OMB could still name WuXi AppTec on the second pathway alone. The OMB list is due by December 18, 2026, five weeks from today, per the same firms.

Our read: the court win buys WuXi AppTec time with Defense Department business, but the decision that really moves sponsor contracts is OMB’s in December. Nothing in this week’s notice predicts it.

Who else in biotech is still on the 1260H list?

Several genomics names remain. Arnold & Porter’s June analysis lists BGI Group (with seven affiliates), MGI Tech and Novogene among the life sciences entities on the June update. Covington noted at the time that WuXi AppTec was the only WuXi entity named; WuXi Biologics was not on the list.

Alibaba has also sued the department over its own designation, according to Federal News Network. Watch whether other designees cite the WuXi AppTec ruling in their own challenges.

What should sponsors and CDMO buyers do now?

Treat the delisting as a reprieve, not a resolution. Here is our working checklist for supply and procurement teams.

BioMed Nexus framework: five checks after the WuXi AppTec delisting

Map federal exposure. List every contract, grant or loan with a federal agency that touches biotechnology equipment or services. That is where BIOSECURE bites.
Separate DoD from everyone else. Section 805 covers only Defense Department contracts. BIOSECURE covers executive agencies broadly once the FAR is revised.
Keep the dual source plan warm. Do not unwind second source tech transfers started in June. Relisting is expressly allowed, and the OMB list lands in December.
Calendar December 18, 2026. The OMB list is the next binary event. Build a decision tree for named and not named outcomes.
Read contract termination clauses. Customers cancelled within weeks of the June listing, per the court record as described by Greenberg Traurig. Know your exit costs before the next designation cycle.

What to watch next

OMB’s initial list of biotechnology companies of concern, due by December 18, 2026.
Whether the Defense Department appeals the injunction or builds a new record for relisting.
The next annual 1260H list update.
Section 805’s indirect ban on June 30, 2027, and the DFARS rule that implements it.
Other designees, including Alibaba, using the WuXi AppTec ruling in their own suits.

FAQ

Is WuXi AppTec still on the Pentagon’s Chinese military companies list?

No. A Defense Department notice published in the Federal Register on November 10, 2026 removed it from the Section 1260H list, in compliance with an August 7, 2026 preliminary injunction from the federal district court in Washington.

Why was WuXi AppTec removed from the 1260H list?

Because a court enjoined the designation. The judge granted a preliminary injunction on August 7, 2026, and the Defense Department delisted the company to comply, without conceding the merits.

Can WuXi AppTec be relisted?

Yes. The notice states the removal is without prejudice to relisting the company on additional or supplementary grounds, and the list is republished annually through 2030.

What is the Section 1260H list?

It is the Defense Department’s list of “Chinese military companies” operating in the United States, required by Section 1260H of the fiscal 2021 NDAA and published in the Federal Register.

What is Section 805 of the fiscal 2024 NDAA?

It bars the Defense Department from contracting with 1260H listed entities. The direct ban took effect June 30, 2026, and an indirect ban on products incorporating their goods or services starts June 30, 2027.

Does the delisting mean WuXi AppTec is clear of the BIOSECURE Act?

No. BIOSECURE lets OMB designate a biotechnology company of concern directly, without the 1260H list. Legal analysts note the injunction binds only the Defense Department, not OMB.

When is the BIOSECURE list due?

OMB’s initial list of biotechnology companies of concern is due by December 18, 2026, one year after the law was signed, according to multiple law firm analyses.

When do BIOSECURE contracting bans actually start?

Law firms say prohibitions take effect 60 or 90 days after the Federal Acquisition Regulation is revised, which follows the OMB list. Greenberg Traurig estimates the outer limit for that revision at about June 2028.

Is WuXi Biologics on the 1260H list?

It was not named in the June 2026 update, according to Covington, which noted WuXi AppTec was the only WuXi entity on that list.

Which other biotech companies are on the 1260H list?

Arnold & Porter lists BGI Group and seven affiliates, MGI Tech and Novogene among life sciences entities in the June 2026 update.

Sources

U.S. Department of Defense, “Notice of Removal of Designated Chinese Military Company,” FR Doc. 2026-22840, published November 10, 2026 (primary): https://public-inspection.federalregister.gov/2026-22840.pdf
Department of Defense Office of Industrial Base Policy, Section 805 waiver request page (primary): https://www.businessdefense.gov/805-waiver-request.html
Reuters via SRN News, November 9, 2026 (attributed: list size, company filing quotes)
Investing.com via Yahoo Finance, November 10, 2026 (attributed: complaint date)
Greenberg Traurig, “BIOSECURE Act Update: Court Enjoins WuXi AppTec’s 1260H Designation,” September 3, 2026 (attributed: case details, court reasoning, timeline)
Ropes & Gray, “BIOSECURE Act Enacted,” January 2026; Arnold & Porter, December 23, 2025 and June 16, 2026; Latham & Watkins, December 31, 2025 (attributed: BIOSECURE structure and deadlines)
Covington, Inside Government Contracts, June 26, 2026 (attributed: WuXi entities on June list)
Federal News Network, July 2026 (attributed: Section 805 guidance, Alibaba suit)

Related coverage

Get the daily read on biotech, pharma and medtech: subscribe to BioMed Nexus.